Brisbane, Australia
Cnn
B (b (b (
An Australian man lived 100 days with artificial titanium heart, while he waited for a donor transplant, which is the longest time in the history of anyone with a technology.
The patient, a man of the 40s, who refused to identify, received an implant during a surgery at St. Vincent’s Hospital Sydney last November.
In February, he became the first person to leave the hospital with the device, who kept him alive until the heart donor was available earlier this month.
According to a statement released Wednesday by the US Australian company, Biocor, behind the St. Vincent Hospital, Monash University and the device, the man, who had a severe heart failure, “is recovering.”
The ability to maintain this device for such a long time is being celebrated as a sign that artificial heart can potentially offer a long -term option for people suffering from heart failure. The device is still being tried and has not yet been approved for general use.
“It is a pleasure to see decades of work,” said Daniel Tomes, the founder of biocur, Australian bioche engineer, who invented his father’s heart disease.
“The entire team of Biocor is deeply grateful to the patient and his family that they should trust our total artificial heart,” he said in a statement. “His bravery will pave the way for more patients to achieve this life -saving technology.”
Biocor is the same dynamic part of the total synthetic heart (TAH), a levyed rotor that is placed in place by magnet. As the name suggests, it is built from the titanium and there is no valves or mechanical bearings that are sensitive to wearing.
It pumps blood on the body and the lungs, which is replaced by both the ventricle of the failed heart.
Cardiovascular diseases are the leading cause of death globally every year, According to the World Health Organization.
Reducing the risk of heart disease
The long -term desire is to use the device to save more people who are on the waiting lists for appropriate donors. According to the US Department of Department, about 3,500 people received heart transplant in 2024. The same year, about 4,400 joins the waiting list.
Biocor Hart started a “full new ball game for heart transplantation,” said Chris Hard, a professor at Victor Chang Cardiac Research Institute.
“Within the next decade, we will see artificial hearts for patients who are unable to wait for the heart or when the donor’s heart is not readily available,” Herd said, who is monitoring Australian patient recovery and was involved in preparing this device for clinical trials.
The device has already been tested at the initial feasibility study of the Food and Drug Administration in the United States, in which five patients were successfully applied with the device.
The first of July was July, when a 58 -year -old was suffering from a heart failure of the last phase who received an implant during surgery at the Texas Medical Center. He kept it alive for eight days until no donor was available.
In this study, four other patients followed, who reviewed the device’s safety and performance, while they waited for the donor transplant. It is hoped that the trial will spread to 15 patients.
The Australian implant was planned by the Artificial Heart Frontiers Program at Monash University, the Australian Implant for the manufacture and commercial treatment of heart failure LEREE.
